BIOTECHNOLOGY EUROPE-NORTH AMERICA NEWS

Community

Advertising Opportunities

Biotechnology Europe Programs

Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

BIOTECHNOLOGY EUROPE-CALIFORNIA

03.11.2008 Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York

06.10.2008 Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

03.10.2008 Amgen Appoints Francois de Carbonnel to the Company's Board of Directors

30.09.2008 Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology

22.08.2008 FDA Approves NplateTM for Long-Term Treatment of Adult Chronic ITP

13.08.2008 Genentech Special Committee of Independent Directors Responds to Roche Proposal

16.04.2008 Amgen Announces Webcast of 2008 First Quarter Financial Results

15.04.2008 Amgen Presents Preclinical and Clinical Data from Oncology Programs

14.04.2008 Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis

14.04.2008 Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types

03.03.2008 Genentech Announces March 14 Webcast of Investment Community Meeting

05.02.2008 ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

06.12.2007 Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs

05.12.2007 Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer

15.10.2007Genentech Announces Third Quarter 2007 Results

21.09.2007 Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union

21.09.2007 Amgen Oncology Highlights Upcoming Data Presentations at the 2007 European Conference on Clinical Oncology

11.09.2007 Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee

15.08.2007 Amgen Restructures Due to Lower Aranesp(R) Revenues While Continuing to Invest in Innovation and Future Growth

01.08.2007Dennis Fenton, Executive Vice President of Operations, Elects to Retire after 25 Years with Amgen

01.08.2007 ACADIA Pharmaceuticals to Present at the Canaccord Adams 27th Annual Global Growth Conference

31.07.2007Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology

30.07.2007 ACADIA to Host Conference Call and Webcast on Monday, August 6, 2007, at 5:00 p.m. Eastern Time

26.07.2007 Amgen's Second Quarter 2007 Adjusted Earnings Per Share Increased 7 Percent to $1.12

18.07.2007 Amgen Completes Acquisition of Ilypsa

11.07.2007 Genentech Announces Second Quarter 2007 Results

11.07.2007 Amgen Announces Webcast of 2007 Second Quarter Financial Results

25.05.2007 Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)

24.05.2007 Amgen Prices $4 Billion of Senior Notes in Three Series; Company to Purchase Approximately $3 Billion in Common Stock

09.05.2007 Sage Group Expands Team – Charles Casamento Joins As New Executive Director

11.04.2007 Genentech Announces First Quarter 2007 Results

11.04.2007 Amgen Announces Webcast of 2007 First Quarter Financial Results

10.04.2007 Amgen Names Robert Bradway Executive Vice President and Chief Financial Officer

23.03.2007 Genentech to Provide Business Update at Annual Investment Community Meeting

22.03.2007 Amgen Discontinues Vectibix(TM) Treatment in PACCE Trial Evaluating Vectibix(TM) as Part of Triple Combination Regimen

22.03.2007 Amgen Discontinues Vectibix(TM) Treatment in PACCE Trial Evaluating Vectibix(TM) as Part of Triple Combination Regimen

19.03.2007 ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial

09.03.2007 Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)

09.03.2007 Genentech Announces March 23 Webcast of Investment Community Meeting

28.02.2007 Amgen to Participate in Goldman Sachs 'In Your Office' Call

28.02.2007 Amgen to Participate in Oncologic Drugs Advisory Committee in May

22.02.2007 Analysis of International Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer

21.02.2007 Genentech Provides Update on Cabilly Patent Reexamination

16.02.2007 Amgen to Hold Analyst Call to Discuss Danish Head and Neck Cancer (DAHANCA) 10 Study

15.02.2007 Amgen Announces Proposals to Declassify Board to Be Presented at 2007 Annual Meeting and Adopts Majority Vote Bylaw

15.02.2007 Genentech Announces Additional Effort to Support Patient Access

06.02.2007 Amgen CEO Kevin Sharer to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

31.01.2007 Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032

25.01.2007 Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion

17.01.2007 Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations

16.01.2007 Amgen Launches 2007 Breakaway from Cancer Initiative

10.01.2007 Genentech Announces Full Year and Fourth Quarter 2006 Results

08.01.2007 Genentech Again Named One of FORTUNE's "100 Best Companies to Work For"

08.01.2007 Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization

of SGN-40

03.01.2007 Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure

14.12.2006 Key Herceptin Data Presented at San Antonio Breast Cancer Symposium

12.12.2006 Updated Interim Long-Term Follow-up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients with Immune Platelet Disorder

10.12.2006 Final Phase 2 Data Continue to Show Promising Results after One Year of Aranesp(R) Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS)

04.12.2006 Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy

01.12.2006 Amgen Names Yuji Orihara President, Amgen KK

20.11.2006 Actelion announces definitive agreement to acquire US-based CoTherix, Inc.

16.11.2006 FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer

16.11.2006 Amgen Launches ChemoCoach.com and ''My Cancer Coach'' Contest in Conjunction with Sponsorship of College Hoops Classic Benefiting Coaches vs. Cancer

13.11.2006 Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years

10.11.2006 Genentech Announces Agreement to Acquire Tanox for $20 Per Share

19.10.2006 Novocell, Inc. Announces Creation Of Insulin-Producing Pancreatic Endocrine Cells From Human Embryonic Stem Cells

I back I top I

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com